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Estrogen is believed to provide females with endogenous protection against cerebrovascular 
events although clinical trials studying long-term hormone replacement have yielded 
disappointing results.  In contrast, estrogen may be neuroprotective following experimental 
ischemia.  We performed a systematic review of controlled experimental studies that 
administered estrogen prior to, or following, cerebral ischemia and measured lesion volume.  
Relevant studies were found from searching PubMed, Embase and Web of Science.  From 
161 identified publications, 26 studies using 1,247 experimental subjects were analysed using 
the Cochrane Review Manager software.  Estrogen reduced lesion volume in a dose-
dependent manner, following either transient (P < 0.001) or permanent (P <0.001) ischemia 
and whether it was given before or up to 4 hours after ischemia onset; no studies assessed 
efficacy for later time periods.  The effect size for estrogen decreased with increasing quality 
scores for studies of transient ischemia.  Estrogen reduced lesion volume when administered 
to ovariectomised females and young adult males, but had no effect in intact females.  
Limited data were present for aged animals and the full dose-response relationship was not 
available in all experimental groups.  On the basis of these data, estrogen is a candidate 











Prior to the menopause, women have a lower risk of stroke relative to men of the same age 
(Kannel and Thom, 1994; Sacco et al., 1997).  Following the menopause, the incidence of 
stroke in women rapidly increases (Wenger et al., 1993), coincident with diminished 
circulating levels of estrogen and progesterone.  Thus, steroid hormones appear to provide 
females with a certain degree of endogenous protection against stroke occurrence and stroke 
damage.   
Experimental studies also support the concept that steroid hormones provide females 
with endogenous protection against stroke.  These animal studies demonstrate that; females 
suffer less ischemic damage than males, the protection in females is absent following 
ovariectomy, and exogenously applied estrogen reduces ischemic damage in males and 
females (for reviews, see Murphy et al., 2004; Simpkins et al., 2005).  Such observations have 
been replicated across a variety of species, strains, and research laboratories, and the 
outcomes from experimental animal studies have been fundamental in supporting the need for 
clinical trials of estrogen. 
Hormone replacement therapy (HRT) has been widely tested in clinical trials aimed at 
reducing the occurrence of vascular events.  Whilst some studies reported a significant 
reduction in stroke occurrence after HRT (Finucane et al., 1993; Henderson et al., 1991), 
others found no significant benefit (Bushnell et al., 2001; Pedersen et al., 1997; Petitti et al., 
1998; Viscoli et al., 2001).  More recently, the Women’s Health Initiative (WHI) trial 
assessing the effect of HRT on incidence and outcome after stroke and other events, was 
halted prematurely because of increased hazard (Wassertheil-Smoller et al., 2003).  A 
systematic review of completed clinical trials found that HRT was associated with an elevated 
risk of stroke, which was ischemic in type and of increased severity (Bath and Gray, 2005). 
The discrepancy in findings between long-term clinical use (HRT increases stroke) 
and short-term use in pre-clinical models of ischemia (estrogen may be neuroprotective) 
findings remains unexplained.  Key factors include the relationship between the design of 
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clinical and experimental studies and interpretation of the latter in terms of dose, timing of 
administration, sex, and age.   
In order to evaluate the neuroprotective potential of estrogen we have performed a 
systematic review to investigate the neuroprotective properties of estrogen on lesion volume 
following experimental stroke, including with regards to timing of treatment, therapeutic 
dose, and effectiveness according to sex and age.   
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Materials and methods 
 
Study Identification 
Experimental controlled studies of the effects of exogenous estrogen on infarct size in animal 
models of stroke were identified from Pubmed, Embase, and Web of Science by searching for 
all articles published by the end of 2004.  Additional publications were identified from 
reference lists of all identified publications and non-systematic review articles (Garcia-Segura 
et al., 2001; Green and Simpkins, 2000; Hurn and Brass, 2003; Hurn and Macrae, 2000; 
McCullough and Hurn, 2003; Wise, 2002; Wise et al., 2001; Yang et al., 2001).  The search 
strategy employed the following keywords: estrogen or estradiol, ischaemia, and cerebral.   
 
Data Extraction 
Two authors (CG, LG) independently extracted data from relevant publications on animal 
species, number, gender and estrogen status, model if ischemia (permanent, transient), 
intervention (estrogen dose, timing relevant to induction of ischemia), and infarct volume 
(mm
3
, % of normal brain, mean, standard deviation).  Where the number of animals per group 
was reported as a range, the lowest numerical value given was used.  If studies used multiple 
groups, e.g. to assess dose-response relationships, then the data from each group were 
individually extracted for analysis.  Infarct volumes were classified as total, and, if available, 
subcortical and cortical.  Occasionally, numerical data were not reported in text and these 
were extracted from enlarged, photocopied figures. 
The methodological quality of each study was assessed using an 8-point ‘STAIR’ 
(1999) rating, as previously described (Horn et al., 2001; Willmot et al., 2005).  One point 
was given for written evidence of each of the following criteria; presence of randomisation; 
monitoring of physiological parameters; assessment of dose response relationship; assessment 
of optimal time window; blinded outcome measurement; assessment of outcome at days 1-3; 





The data were analysed as forest plots using Cochrane Collaboration Review Manager 
(RevMan Version 4.2) software; an example is given in figure 1.  Results are given as 
standardised mean difference (SMD) which allows the merging of data measured on different 
scales, with 95% confidence intervals (CI).  A random effects model was used because 
statistical heterogeneity was likely to be present due to the use of different protocols.  
Statistical heterogeneity was assessed with a χ
2
 test.  Study data were grouped by pre-
specified criteria: experimental model (permanent or transient) and location of lesion (total, 
cortical, sub-cortical). 
In order to examine the effects of study characteristics and potential sources of 
heterogeneity on outcome, stratified meta-analyses were performed with experiments grouped 
according to: (i) trial quality score; (ii) population grouping - all animals, adult males, 
ovariectomised females, intact females, aged females, aged males; (iii) lesion location; (iv) 
estrogen dose; and (v) timing of estrogen administration in relation to onset of ischemia. 
A random effects model was used because statistical heterogeneity was likely to be 
present due to the use of different protocols.  Sensitivity analyses were performed to identify 
possible sources of heterogeneity including: study quality, lesion location, population 
grouping, dose range, and timing of estrogen administration in relation to onset of ischemia.  
Publication bias was assessed using Egger’s asymmetry test (STATA function “metabias” 




Design of Studies 
The literature search identified 161 potential articles, although a large number of these were 
excluded for the reasons given in Figure 2.  The characteristics of the remaining 26 studies are 
reported in Table 1.  All of the included studies reported the effect of exogenously applied 
estrogen on infarct volume following cerebral ischemia.  The 26 studies represented the 
outcome from 9 independent research groups.  Within the 26 studies, data from a total of 
1,247 experimental subjects were included for analysis. 
The majority of studies employed a model of transient focal ischemia (17 studies) 
with 9 studies reporting the effect of estrogen following permanent focal ischemia.  A study 
of estrogen following global ischemia (Horsburgh et al., 2002) was excluded since data on 
lesion volume were not reported.   
Various rat strains (Wistar, Sprague-Dawley, Spontaneously Hypertensive, and 
Reproductively Senescent) were used in 24 out of the 26 included studies; 2 studies used 
mice.  Methodological design was variable as far as drug administration was concerned.  
Several routes of administration (subcutaneous, intraperitoneal, intravenous, 
intracerebroventricular) were used with first dose timings in relation to onset of ischemia 
varying from 10 days prior, to 4 hours following.  
In terms of outcome measure, lesion volume was assessed by histological staining 
and reported as: lesion volume (mm
3
), % of total cross-sectional area, or % of ipsilateral non-
ischemic total/region.  An exception to this was the study by Shi et al (2001), which used 
structural  MRI to determine lesion size. 
Publication bias was present for studies reporting the effect of estrogen administration 





Reported Study Quality 
The median STAIR rating for included articles was 3 (range 1-4 out of 8).  Animals allocated 
treatment by randomisation was reported in only two studies (Toung et al., 1998, 2004).  All 
but two studies (Wise, 2000; Yang et al., 2003) reported the monitoring of physiological 
parameters, with most only monitoring body temperature.  Eight studies  assessed dose-
response relationships (Choi et al., 2004; Culmsee et al., 1999; Dubal et al., 1998, 2001; Rusa 
et al., 1999; Toung et al., 1998; Vergouwen et al., 2000; Yang et al., 2000) and eight studies 
investigated the optimal time window of estrogen administration (Dubal et al., 1998; Fukada 
et al., 2000; McCullough et al., 2001; Rau et al., 2003; Saleh et al., 2001; Simpkins et al., 
1997; Vergouwen et al., 2000; Yang et al., 2000).  All but two studies (Saleh et al., 2001; Shi 
et al., 2001) assessed outcome at days 0-3; one study (Simpkins et al., 1997) assessed 
outcome at days 7-30, and another (Santizo et al., 2002) reported combined measurement of 
lesion volume and functional outcome.  The latter was the only study to report outcome 
measures being blinded to treatment.  
Following permanent ischemia a beneficial effect of estrogen treatment was observed 
regardless of reported quality score (P < 0.001, Figure 3A).  The majority of studies utilised 
the model of transient focal ischemia and the beneficial effect of estrogen administration 
decreased with increasing reported quality score (Figure 3B).  In fact, there was no beneficial 
effect of estrogen administration in studies that obtained a quality score of 4 which was the 
highest score awarded (P = 0.39).   
 
Infarct Volume According to Hormonal Status/Age 
The effects of estrogen on total, cortical and subcortical lesion volume were analysed (Figure 
4) according to population groupings based on hormonal status/age (i.e. males, 
ovariectomised females, intact females, aged females, aged males). 
Estrogen administration significantly reduced total lesion volume following 
permanent (P < 0.001) and transient ischemia (P = 0.002, Figure 4A).  Following permanent 
ischemia estrogen had a slightly greater beneficial effect in ovariectomised females compared 
 9 
to males.  Following transient ischemia, the largest effect of estrogen on total lesion volume 
was also seen in ovariectomised females.  However, estrogen treatment appeared to have a  
detrimental effect when administered to intact females (Figure 4A) although this was not 
significant (P = 0.06).  For total lesion volume, hormonal status accounted for a significant 
amount of between-group heterogeneity following both permanent (χ
2
 = 61.3, df = 35, P = 
0.004) and transient ischemia (χ
2
 = 107.7, df = 40, P <  0.00001). 
Estrogen treatment significantly reduced cortical lesion volume when measured 
following permanent (P < 0.001) and transient ischemia (P < 0.001, Figure 4B).  The effects 
of estrogen on cortical lesion volume following permanent ischemia have only been reported 
in ovariectomised females and between-group heterogeneity analysis was not possible.  
Following transient ischemia, estrogen treatment was most effective at reducing cortical 
lesion volume in aged females, although this was based on data extracted from one published 
study (Figure 4B).  For cortical lesion volume following transient ischemia, hormonal status 
accounted for a significant portion of between-group heterogeneity (χ
2
 = 21.9, df = 11, P = 
0.02). 
In addition, estrogen treatment significantly reduced subcortical lesion volume when 
measured following permanent (P < 0.001) and transient ischemia (P < 0.001, Figure 4C).  
Again, the effects of estrogen on subcortical lesion volume following permanent ischemia 
were only examined in ovariectomised females.  Following transient ischemia (one study), 
estrogen treatment was most effective at reducing cortical lesion volume in aged females 
(Figure 4C).  For subcortical lesion volume following transient ischemia, hormonal status 
accounted for a significant portion of between-group heterogeneity (χ
2




Taking all animals into account, i.e. regardless of age/hormonal status, estrogen significantly 
reduced lesion volume following permanent (P < 0.001) and transient ischemia (P < 0.004, 
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Figure 5A).  The effect of estrogen on reducing lesion volume appeared to increase with 
increasing dose.  Estrogen dose accounted for a significant amount of between-group 
heterogeneity following both permanent (χ
2
 = 61.21, df = 34, P = 0.003) and transient 
ischemia (χ
2
 = 113.56, df = 41, P <  0.001). 
In an attempt to identify any gender differences in response to different estrogen 
doses, the data were analysed for males (Figure 5B) and ovariectomised females (Figure 5C).  
In males, the effect of estrogen on reducing lesion volume was increased with increasing dose 
(Figure 5B).  However, in ovariectomised females no studies have reported the effect of 
administering estrogen within the dose range (3.1 - 30.0 mg/kg) that gave the best result in 
males. 
 
Timing of estrogen administration in relation to onset of ischemia 
Both pre- and post-ischemic estrogen administration were effective at reducing lesion volume 
in all animals following permanent (P < 0.001) and transient ischemia (P = 0.006, Figure 6A).  
However, no studies examined the effects of administering estrogen later than 6 hours 
following onset of ischemia.  Timing of estrogen administration accounted for a significant 
portion of between-group heterogeneity following both permanent (χ
2
 = 61.2, df = 34, P = 
0.003) and transient ischemia (χ
2
 = 112.2, df = 40, P = <0.001). 
For permanent ischemia, estrogen only significantly reduced lesion volume in males 
when administered -21 days to -2 hours prior to surgery (Figure 6B).  Due to the small 
number of studies investigating the neuroprotective effects of estrogen in males following 
transient ischemia it is not possible to identify an ideal time of administration. 
In ovariectomised females, estrogen treatment had the greatest effect when 
administered immediately following (i.e. 0h to +2h) permanent ischemia (P < 0.001) or 
immediately before (i.e. -2h to 0h) transient ischemia (P = 0.02, Figure 6C).  However, the 
majority of studies administered estrogen between 21 days and 2 hours prior to ischemia 




This systematic review has found that estrogen reduces lesion volume following either 
transient or permanent ischemia.  However, following transient ischemia, the effect of 
estrogen treatment decreased with increased reported quality score.  When studies were 
grouped according to hormonal status and age, estrogen treatment was only effective in 
ovariectomised females and young adult males.  Importantly, studies of estrogen in aged 
animals and its administration later than 4 hours following ischemia were lacking.  
Additionally, adequate dose response relationships of estrogen has not been fully investigated 
in all experimental groups. 
This review focuses only on the effect of estrogen on lesion volume following stroke, 
due to insufficient data regarding other outcomes such as behaviour; only one study examined 
the functional benefits of estrogen administration in both males and females up to 14 days 
following experimental ischemia (Li et al., 2004).  However, lesion volume is of limited value 
when interpreting whether a treatment is beneficial.  Functional outcome, in combination with 
histopathological outcome, is as important in terms of assessing benefit (STAIR, 1999).  
Infarct size may (Rogers et al., 1997) or may not (Hattori et al., 2000; Reglodi et al., 2003; 
Wahl et al., 1992) correlate with neurological impairment.  The STAIR criteria (STAIR, 
1999) emphasise the need to determine functional effects of interventions. 
Whilst estrogen appeared to be effective in young adult males and ovariectomised 
females, it may have been hazardous in intact females.  Assessments in ovariectomised 
females are not an ideal model of post-menopausal women.  In experimental studies young 
female animals are subjected to a sudden surgical removal of estrogen supply, whereas 
humans who enter the menopause, at a mean age of 51 years in the USA (Creasman et al., 
2003), experience a slow decline of circulating estrogen levels over months or even years.   
Importantly, there is a substantial lack of data in the literature reporting the effects of estrogen 
administration in aged animals, yet the incidence of stroke in humans is strongly age-
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dependent (Wolf et al., 1992).  Although studies on aged animals are not usually undertaken 
because of expense, these represent but a fraction of the costs of failed clinical trials.   
The neuroprotective effects of estrogen are dose-dependent, with studies 
administering estrogen at doses considered to be either physiological (Dubal et al., 1998) or 
pharmacological (Simpkins et al., 1997).  In males and ovariectomised females the effect of 
estrogen on reducing lesion volume increased with increasing dose.  However, the higher 
doses administered in males have not been applied to ovariectomised females.  Thus, there is 
a need to further explore the dose-response relationship of estrogen and neuroprotection.  
Additionally, the long term benefits of estrogen treatment are not fully understood.  In fact, 
where histological outcome was assessed at 7 days following ischemia, physiological levels 
of estrogen had a detrimental effect on cell death in the vulnerable CA1 region of the 
hippocampus (Harukuni et al., 2001).  Importantly, no studies reported administering estrogen 
at later than 4 hours following ischemia.  As the majority of those at greatest risk of suffering 
a stroke are not receiving HRT (i.e. men and post-menopausal women), such a time window 
of application is not clinically relevant.   Thus, this review emphasises the need for bi-
directional translational research between experimental and clinical studies. 
Although it is well recognised that premenopausal women have an endogenous 
protection against vascular events, the importance of other steroid hormones must also be 
considered.  For example, progesterone has been shown to reduce lesion volume following 
both permanent (Gibson et al., 2005) and transient experimental ischemia (Gibson and 
Murphy, 2004; Murphy et al., 2002), and also to improve functional outcome (Gibson and 
Murphy, 2004).  Although experimental studies have shown that progesterone is 
neuroprotective when administered prior to or following cerebral ischemia in males and 
ovariectomised females, no clinical studies to date have investigated the effects of 
progesterone on outcome following stroke. 
Systematic review and meta-analysis are fundamental tools in the interpretation of the 
effectiveness of a particular treatment across a large number of studies.  However, they do 
have various limitations.  Firstly, analyses can only include available data, usually only 
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available in published studies.  Negative or neutral studies are less likely to be published so 
the results meta-analysis may overstate effect size.  In fact, Egger’s asymmetry test did 
suggest publication bias was likely which could have resulted from the lack of reporting 
neutral or negative studies.  Consequently, the benefits of estrogen on infarct volume might 
have been either over or underestimated.  Additionally, non-publication will limit available 
information on the effect of treatment within certain protocol aspects such as dose or time of 
administration.   
In respect of study quality, we could only judge the studies as reported; a low quality 
score could reflect either that the authors did not undertake that procedure, e.g. randomise 
animals to treatment, or that they did not report it.  Authors, journal reviewers and editors 
need to be more stringent in reporting key methodological details.  A particular area of 
concern is that the majority of studies did not report randomisation and/or blinded assessment 
of outcome.  Lack of randomisation and blinded assessment of outcome are key sources of 
bias and will over-emphasise treatment efficacy.  Additionally, whilst most studies reported 
physiological parameters, the majority only assessed body temperature.  Although body 
temperature is a useful indicator, additional physiological parameters also give invaluable 
information about the physiological effects of a particular treatment which could be crucial 
when considering the design of clinical trials. 
There is a need to determine precisely the cellular targets and molecular events triggered 
by estrogen administration.  Animal studies can be fundamental in determining the optimal 
estrogen treatment in terms of timing and dosing amongst different populations.  However, 
this review has highlighted fundamental areas where experimental evidence demonstrating a 
protective effect of estrogen is lacking.  It is these areas which should focus research in order 
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Figure Legends 
FIG. 1 A forest plot showing total lesion volume following permanent ischemia.  N, number 
of animals; SMD, standardized mean difference; 95% CI, 95% confidence interval; SD, 
standard deviation. 
 
FIG. 2 Search process showing reasons for exclusions of studies.  N = number of studies. 
 
FIG. 3 SMD and 95% CI by reported STAIR score following permanent (A) and transient (B) 
ischemia.  N = number of animals; S = number of studies. 
 
FIG. 4 SMD and 95% CI for total (A), cortical (B), and subcortical (C) lesion volume.  Data 
shown following permanent and transient ischemia is grouped according to age and hormonal 
status of animals.  OV, ovariectomised; N, number of animals; S, number of studies. 
 
FIG. 5 SMD and 95% CI for total lesion volume following permanent and transient ischemia 
in all animals (A), males (B), and ovariectomised females (C).  Data is grouped according to 
dose of estrogen given (mg/kg, where reported).  N, number of animals; S, number of studies. 
 
FIG. 6 SMD and 95% CI for total lesion volume following permanent and transient ischemia.  
Data is grouped according to time of first administration of estrogen.  N, number of animals; 
S, number of studies. 





Table 1 Characteristics of Included Studies. 
Study Year Species Sex/hormonal 
status 






 dose timing 
(hr/day) 




Alkayed 2000 WR M, RSF A, N F, T 0.025 -7d s.c. % CBF 
Choi 2004 SDR M N F, T 1.0 - 10.0 -24h i.p. %  
Culmsee 1999 NM M N F, P 0.0003 - 30.0 -24h s.c., i.p. mm
3
  
Dubal 1998 SDR OF N F, P NR -7f s.c. mm
3
  
Dubal 2001 SDR OF A, Y F, P NR -7d s.c. mm
3
  
Dubal  2001 CM OF N F, P NR -7d s.c. mm
3
  
Fan 2003 SDR OF N F, T 0.1 -2h s.c. %  
Fukada 2000 SHR OF N F, T 0.2 -21d s.c. mm
3
 CBF 
Green 2001 SDR OF N F, T 0.1 -2h s.c. %  
Hawk 1998 SDR M N F, T NR -7d s.c. %  
Liu 2002 SDR OF N F, T 0.1 -2h s.c. mm
3
 CBF 
McCullough 2001 WR M N F, T 1.0 0h i.v. % CBF 




Rusa 1999 WR OF N F, T 0.25 - 1.0 -7d s.c. % CBF 
Saleh 2001 SDR M N F, P NR -0.5h i.c.v. %  
Santizo 2002 SDR OF N F, T 0.1 -7d i.p. % NS 
Shi 2001 SDR OF N F, T 0.1 -2h s.c. MRI CBF 
Simpkins 1997 SDR OF N F,T 1.0 -24h s.c. %  
Toung 1998 WR M N F, T 0.025 - 1.0 -7d s.c. %  
Toung 2000 WR M N F, T 0.025 -10d s.c. %  
Toung 2004 RSFR RSF A F, T 0.025 -7d s.c. %  
Vergouwen 2000 WR M, F, OF N F, T 0.1 - 1.0 -10d i.v. mm
3
  
Wise 2000 SDR OF N F, P 0.18 -7d s.c. mm
3
  
Yang 2000 SDR F, OF N F, P 0.1 +4h s.c. % CBF 
Yang 2003 SDR OF N F, P 0.1 - 5.0 +0.5h s.c. mm
3
  
Zhang 1998 SDR OF N F, T 1.0 +0.6h i.v. %  
Abbreviations: WR, Wistar rats; SDR, Sprague-Dawley rats; NM, NMRI mice; CM, C57 mice; SHR, spontaneously hypertensive rats; RSFR, reproductively 
senescent female rats; M, males; OF, ovariectomised females; RSF, reproductively senescent females; F, intact females; A, aged; N, normal adult; Y, young; 
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F, focal; T, transient; P, permanent; NR, not reported; s.c., subcutaneous; i.p., intraperitoneal; i.c.v, intracerebroventricular; i.v., intravenous; CBF, cerebral 
blood flow; NS, neurological score.  
